HIPK1 Knockout HEK293T Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population designed for targeted disruption of the HIPK1 gene. This product leverages CRISPR/Cas9 technology to generate a heterogeneous pool of HEK293T cells harboring loss-of-function mutations in HIPK1, providing a versatile and reliable model for studying HIPK1-dependent biological processes. The polyclonal format ensures population-level gene inactivation, minimizing clonal variation and enabling consistent functional genomics applications.
The host cell line, HEK293T, is a human embryonic kidney epithelial cell line immortalized by the SV40 large T antigen. This modification confers high transfection efficiency and robust protein expression, rendering HEK293T cells ideal for overexpression, reporter gene, and biochemical assays. Originating from renal epithelium, these cells recapitulate many signaling pathways relevant to kidney biology and cancer, making them a standard workhorse for molecular and cellular research.
HIPK1 encodes a serine/threonine kinase that functions predominantly as a transcriptional corepressor. It is activated downstream of TGF-?? and Wnt ligands, and in response to DNA damage signals, interacting directly with homeodomain proteins and TLE co-repressors. HIPK1 phosphorylates and modulates the activity of transcription factors including p53, c-Myb, NKX3.1, and the TGF-?? effector SMAD3. These interactions place HIPK1 at the center of a network that integrates TGF-??, Wnt, p53, and MAPK signaling to regulate gene expression programs controlling apoptosis, cell cycle progression, and cellular differentiation. Key pathway components such as TGFBR1, SMAD2/3, BAX, and c-MYB are all functionally linked to HIPK1, underscoring its pleiotropic regulatory roles.
In HEK293T cells, which endogenously express many of these signaling molecules, knockout of HIPK1 disrupts the phosphorylation-dependent crosstalk between TGF-??/Wnt pathways and transcriptional regulators. This disruption can alter responses to stress, proliferation cues, and developmental signals, providing a tractable model to dissect HIPK1’s mechanistic contributions. The polyclonal nature of the edited population avoids the artifacts associated with single-cell clones, such as off-target effects and genetic drift, ensuring that observed phenotypes reflect genuine gene disruption. This model is particularly valuable for studying how HIPK1 loss affects downstream targets like p53 and c-Myb in a well-characterized cellular context.
Research applications for these cells span transcriptional regulation studies, where luciferase reporter assays can quantify HIPK1’s corepressor activity, and apoptosis assays (Annexin V/PI staining) to evaluate cell death upon TGF-?? stimulation. The cells are also suited for immunoprecipitation to map protein interaction networks, flow cytometry for cell cycle analysis, and Western blotting to assess phosphorylation status of key targets. In cancer biology, this model aids in validating HIPK1 as a therapeutic target by examining proliferation and survival pathways. For experimental protocols or ordering information, please contact Ascent Research.
